NASDAQ:LNAI Lunai Bioworks (LNAI) Stock Price, News & Analysis $0.33 0.00 (-0.90%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.31 -0.02 (-4.85%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Lunai Bioworks Stock (NASDAQ:LNAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lunai Bioworks alerts:Sign Up Key Stats Today's Range$0.32▼$0.3450-Day Range$0.18▼$0.5652-Week Range$0.15▼$5.50Volume1.19 million shsAverage Volume10.13 million shsMarket Capitalization$7.98 millionP/E Ratio6.60Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California. Read More Lunai Bioworks Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreLNAI MarketRank™: Lunai Bioworks scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingLunai Bioworks has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLunai Bioworks has only been the subject of 1 research reports in the past 90 days.Read more about Lunai Bioworks' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lunai Bioworks is 6.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Lunai Bioworks is 6.60, which means that it is trading at a less expensive P/E ratio than the Manufacturing sector average P/E ratio of about 23.65. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for LNAI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLunai Bioworks does not currently pay a dividend.Dividend GrowthLunai Bioworks does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Lunai Bioworks this week, compared to 1 article on an average week.Search Interest7 people have searched for LNAI on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows1 people have added Lunai Bioworks to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lunai Bioworks insiders have not sold or bought any company stock.Percentage Held by Insiders0.50% of the stock of Lunai Bioworks is held by insiders.Percentage Held by Institutions71.41% of the stock of Lunai Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lunai Bioworks' insider trading history. Receive LNAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lunai Bioworks and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LNAI Stock News HeadlinesFinancial Comparison: Lunai Bioworks (NASDAQ:LNAI) & Merck KGaA (OTCMKTS:MKGAF)May 5, 2026 | americanbankingnews.comLunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IPMay 4, 2026 | prnewswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 9 at 1:00 AM | Profits Run (Ad)Lunai Bioworks Inc.: Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma PartnershipsApril 15, 2026 | finanznachrichten.deLunai Bioworks Unit Signs Preliminary Deal with Geneial on Rare Disease Data CollaborationApril 15, 2026 | msn.comLunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma PartnershipsApril 15, 2026 | prnewswire.comLunai Bioworks Inc.: Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat ...April 7, 2026 | finanznachrichten.deLunai Bioworks unit secures defense collaboration for AI chemical threat platformApril 7, 2026 | msn.comSee More Headlines LNAI Stock Analysis - Frequently Asked Questions How have LNAI shares performed this year? Lunai Bioworks' stock was trading at $0.8817 on January 1st, 2026. Since then, LNAI shares have decreased by 62.6% and is now trading at $0.33. How were Lunai Bioworks' earnings last quarter? Lunai Bioworks Inc. (NASDAQ:LNAI) issued its quarterly earnings results on Tuesday, February, 17th. The company reported ($0.08) earnings per share (EPS) for the quarter. When did Lunai Bioworks' stock split? Shares of Lunai Bioworks reverse split before market open on Tuesday, September 30th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Lunai Bioworks? Shares of LNAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/17/2026Today5/09/2026Fiscal Year End6/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 LNAI's financial health is in the Green zone, according to TradeSmith. LNAI has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LNAI CIK1527728 WebN/A Phone(453) 917-9840FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.05 Trailing P/E Ratio6.60 Forward P/E RatioN/A P/E GrowthN/ANet Income-$178.01 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,243.45% Return on Assets-360.31% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.24) per share Price / Book-0.27Miscellaneous Outstanding Shares24,190,000Free Float24,066,000Market Cap$7.98 million OptionableN/A Beta0.34 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:LNAI) was last updated on 5/9/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lunai Bioworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lunai Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
